BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng-lin B, Ortiz A. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs 2018;78:215-29. [DOI: 10.1007/s40265-017-0858-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Igweonu-nwakile EO, Ali S, Paul S, Yakkali S, Teresa Selvin S, Thomas S, Bikeyeva V, Abdullah A, Radivojevic A, Abu Jad AA, Ravanavena A, Ravindra C, Balani P. A Systematic Review on the Safety and Efficacy of PCSK9 Inhibitors in Lowering Cardiovascular Risks in Patients With Chronic Kidney Disease. Cureus 2022. [DOI: 10.7759/cureus.29140] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Doiron S, Paquette M, Baass A, Bollée G, Cardinal H, Bernard S. Association between circulating PCSK9 and proteinuria in nephrotic syndrome: A cross-sectional study. Clinical Biochemistry 2022. [DOI: 10.1016/j.clinbiochem.2022.08.002] [Reference Citation Analysis]
3 Maligłówka M, Kosowski M, Hachuła M, Cyrnek M, Bułdak Ł, Basiak M, Bołdys A, Machnik G, Bułdak RJ, Okopień B. Insight into the Evolving Role of PCSK9. Metabolites 2022;12:256. [DOI: 10.3390/metabo12030256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Maligłówka M, Bułdak Ł, Okopień B, Bołdys A. The consequences of PCSK9 inhibition in selected tissues. Postepy Hig Med Dosw 2021;75:385-97. [DOI: 10.5604/01.3001.0014.9127] [Reference Citation Analysis]
5 Shrestha P, Adepu S, Vivès RR, Masri RE, Klooster A, Kaptein F, Dam W, Bakker SJL, van Goor H, van de Sluis B, van den Born J. Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction. J Am Soc Nephrol 2021;32:1371-88. [PMID: 33758009 DOI: 10.1681/ASN.2020091376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shrestha P, Yazdani S, Vivès RR, El Masri R, Dam W, van de Sluis B, van den Born J. Proteinuria converts hepatic heparan sulfate to an effective proprotein convertase subtilisin kexin type 9 enzyme binding partner. Kidney Int 2021;99:1369-81. [PMID: 33609572 DOI: 10.1016/j.kint.2021.01.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Su X, Cheng Y, Chang D. Lipid-lowering therapy: Guidelines to precision medicine. Clin Chim Acta 2021;514:66-73. [PMID: 33359059 DOI: 10.1016/j.cca.2020.12.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Wang L, Xiang F, Ji J, Ding X, Shen B, Chen J, Chen Y, Xue N, Zhang L, Jiang X, Cao X. Indoxyl sulfate and high-density lipoprotein cholesterol in early stages of chronic kidney disease. Ren Fail 2020;42:1157-63. [PMID: 33191829 DOI: 10.1080/0886022X.2020.1845731] [Reference Citation Analysis]
9 Lee KM, Chan GCW, Tang SCW. Not even a peripheral role for statins in end-stage renal disease? Nephrol Dial Transplant 2020;35:1645-7. [PMID: 32252067 DOI: 10.1093/ndt/gfaa051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Tao M, Wang HP, Sun J, Tian J. Progress of research on dyslipidemia accompanied by nephrotic syndrome. Chronic Dis Transl Med 2020;6:182-7. [PMID: 32885154 DOI: 10.1016/j.cdtm.2020.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Huang X, Jia Y, Zhu X, Zhang Y, Jiang L, Wei X, Zhao D, Zhao X, Du Y. Effects of Statins on Lipid Profile of Kidney Transplant Recipients: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int 2020;2020:9094543. [PMID: 32462035 DOI: 10.1155/2020/9094543] [Reference Citation Analysis]
12 Huang X, Jia Y, Zhu X, Zhang Y, Jiang L, Wei X, Zhao D, Zhao X, Du Y. Effects of statins on lipid profile of kidney transplant recipients: a meta-analysis of randomized controlled trials.. [DOI: 10.1101/2020.04.07.20057349] [Reference Citation Analysis]
13 Fernandez-Prado R, Perez-Gomez MV, Ortiz A. Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J 2020;13:753-7. [PMID: 33123354 DOI: 10.1093/ckj/sfaa001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
14 Low L, Lu L, Chan C, Chen J, Yang H, Yu H, Lee C, Ng K, Yap H. IL-13-driven alterations in hepatic cholesterol handling contributes to hypercholesterolemia in a rat model of minimal change disease. Clinical Science 2020;134:225-37. [DOI: 10.1042/cs20190961] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Jabarpour M, Rashtchizadeh N, Argani H, Ghorbanihaghjo A, Ranjbarzadhag M, Sanajou D, Panah F, Alirezaei A. The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction. Int Urol Nephrol 2019;51:2235-42. [DOI: 10.1007/s11255-019-02319-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
16 Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C. Lipid management in patients with chronic kidney disease. Nat Rev Nephrol 2018;14:727-49. [PMID: 30361677 DOI: 10.1038/s41581-018-0072-9] [Cited by in Crossref: 97] [Cited by in F6Publishing: 101] [Article Influence: 32.3] [Reference Citation Analysis]
17 Valdivielso JM, Rodríguez-Puyol D, Pascual J, Barrios C, Bermúdez-López M, Sánchez-Niño MD, Pérez-Fernández M, Ortiz A. Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different? Arterioscler Thromb Vasc Biol 2019;39:1938-66. [PMID: 31412740 DOI: 10.1161/ATVBAHA.119.312705] [Cited by in Crossref: 88] [Cited by in F6Publishing: 96] [Article Influence: 29.3] [Reference Citation Analysis]
18 Katsiki N, Mikhailidis DP, Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opinion on Pharmacotherapy 2019;20:2007-17. [DOI: 10.1080/14656566.2019.1649394] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
19 Hari P, Khandelwal P, Smoyer WE. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome. Pediatr Nephrol 2020;35:1601-19. [PMID: 31302760 DOI: 10.1007/s00467-019-04301-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
20 Pryor JB, Weber BR, Weber JV, Lockridge JB, Olyaei AJ. Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review. Drugs Ther Perspect 2019;35:431-41. [DOI: 10.1007/s40267-019-00646-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Schmit D, Fliser D, Speer T. Proprotein convertase subtilisin/kexin type 9 in kidney disease. Nephrology Dialysis Transplantation 2019;34:1266-71. [DOI: 10.1093/ndt/gfz122] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
22 González Sanchidrián S, Labrador Gómez PJ, Aguilar Aguilar JC, Davin Carrero E, Gallego Domínguez S, Gómez-martino Arroyo JR. Evolocumab for the treatment of heterozygous familial hypercholesterolaemia in end-stage chronic kidney disease and dialysis. Nefrología (English Edition) 2019;39:218-20. [DOI: 10.1016/j.nefroe.2018.09.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Shrestha P, van de Sluis B, Dullaart RP, van den Born J. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cellular Signalling 2019;55:53-64. [DOI: 10.1016/j.cellsig.2018.12.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
24 González Sanchidrián S, Labrador Gómez PJ, Aguilar Aguilar JC, Davin Carrero E, Gallego Domínguez S, Gómez-Martino Arroyo JR. Evolocumab for the treatment of heterozygous familial hypercholesterolemia in end-stage chronic kidney disease and dialysis. Nefrologia (Engl Ed) 2019;39:218-20. [PMID: 30545713 DOI: 10.1016/j.nefro.2018.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
25 Dincer N, Dagel T, Afsar B, Covic A, Ortiz A, Kanbay M. The effect of chronic kidney disease on lipid metabolism. Int Urol Nephrol 2019;51:265-77. [DOI: 10.1007/s11255-018-2047-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
26 Kim SH, Jeong HY, Yang DH, Kim J, Lee SY. Beneficial effect of statins in patients receiving chronic hemodialysis following percutaneous coronary intervention: A nationwide retrospective cohort study. Sci Rep 2018;8:9692. [PMID: 29946155 DOI: 10.1038/s41598-018-27941-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
27 Lutz J, Sollinger D, Weinmann-menke J, Rieke A, Schamberger B. Nachsorge nach Nierentransplantation. Nephrologe 2018;13:167-172. [DOI: 10.1007/s11560-018-0242-6] [Reference Citation Analysis]
28 Bulbul M, Dagel T, Afsar B, Ulusu N, Kuwabara M, Covic A, Kanbay M. Disorders of Lipid Metabolism in Chronic Kidney Disease. Blood Purif 2018;46:144-52. [DOI: 10.1159/000488816] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 13.5] [Reference Citation Analysis]